BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Apex Bioventures Acquisition Corporation Completes Initial Public Offering


6/14/2007 11:03:36 AM

NEW YORK, June 13 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (the "Company") announced today that it has closed its initial public offering (the "IPO") of 8,625,000 units, including 1,125,000 units issued upon exercise of the underwriters' over-allotment option. Each unit consists of one share of common stock and one warrant. The units were sold at an offering price of $8.00 per unit, generating gross proceeds to the Company of $69,000,000. Lazard Capital Markets LLC acted as the sole book runner for the initial public offering and Ladenburg Thalmann & Co. Inc. acted as co-representative. A copy of the prospectus may be obtained from Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, New York 10112.

Audited financial statements reflecting receipt of the proceeds upon consummation of the initial public offering by the Company will be included as Exhibit 99.1 to a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.

In addition, the Company announced that, commencing on June 20, 2007, the holders of the Company's units may voluntarily elect to separately trade the common stock and warrants included in the Company's units. Those units not separated will continue to trade on the American Stock Exchange under the symbol PEX.U, and each of the common stock and warrants will trade on the American Stock Exchange under the symbols PEX and PEX.WS, respectively.

Apex Bioventures Acquisition Corporation intends to use the net proceeds from the IPO to effect a merger, capital stock merger, capital stock exchange, asset acquisition, stock purchase or other similar business combination with one or more domestic or foreign operating businesses in the healthcare industry as described in the Company's prospectus.

A registration statement relating to these securities was filed and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of Apex Bioventures Acquisition Corporation, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This public offering will be made only by means of a prospectus, copies of which may be obtained from Lazard Capital Markets LLC.

Apex Bioventures Acquisition Corporation

CONTACT: Darrell J. Elliott, Chairman and Chief Executive Officer of ApexBioventures Acquisition Corporation +1-604-924-0349



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES